Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 01-07-2020 | Vancomycin | Original Article

The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile

Authors: Dorota Wultańska, Michał Piotrowski, Hanna Pituch

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2020

Abstract

This study aims to investigate the antimicrobial and antibiofilm activity of berberine chloride (BBR) and vancomycin (VAN) as well as synergistic combinations of BBR with VAN against Clostridioides difficile strains. The effect of different concentrations of BBR on strain motility was also assessed. Twelve C. difficile strains (two reference C. difficile 630, ATCC 9689, and one control M120, and 9 clinical C. difficile strains belonging to the PCR-ribotype (RT027)) were collected and investigated for their susceptibility to BBR and VAN in planktonic and biofilm forms. Both the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of BBR for the C. difficile strains were found to vary over a broad range (256–1.024 mg/L and 256–16.384 mg/L, respectively). The MIC and MBC of VAN also varied greatly, ranging from 0.25 to 4.0 mg/L for MIC and 0.25 to 64.0 mg/L for MBC. The synergistic effect of the sub-MIC (1/2 MIC) BBR with VAN reduced of MICs of VAN against the planktonic forms of ten C. difficile strains. The sub-MIC of BBR enhanced the biofilm formation of one strain and was found to be statistically significant. In addition, the sub-MIC of BBR with VAN surprisingly enhanced the biofilm formation of one C. difficile strain. The effect of inhibition of motility in the presence of BBR was statistically significant for 3 clinical strains (p < 0.05). Altogether, BBR exhibited strong antimicrobial activity against C. difficile, and the analysis of the combination of BBR with VAN showed a synergistic effect.

Rupnik M, Wilcox MH, Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526–536. https://doi.org/10.1038/nrmicro2164 CrossRefPubMed

Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML et al (2008) Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13:18942PubMed

Lachowicz D, Pituch H, Obuch-Woszczatyński P (2015) Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 31:37–41. https://doi.org/10.1016/j.anaerobe.2014.09.004 CrossRefPubMed

Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ (2016) Clostridium difficile infection. Nat Rev Dis Primers 2:16020. https://doi.org/10.1038/nrdp.2016.20 CrossRefPubMedPubMedCentral

Krutova M, Kinross P, Barbut F, Hajdu A, Wilcox MH, Kuijper EJ, survey contributors (2018) How to: surveillance of Clostridium difficile infections. Clin Microbiol Infect 24:469–475. https://doi.org/10.1016/j.cmi.2017.12.008 CrossRefPubMed

Pituch H, Obuch-Woszczatyński P, Lachowicz D, Wultańska D, Karpiński P, Młynarczyk G, van Dorp SM, Kuijper EJ, Polish Clostridium difficile Study Group (2015) Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013. Euro Surveill:20. https://doi.org/10.2807/1560-7917.ES.2015.20.38.30025

Ðapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M (2013) Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 195:545–555. https://doi.org/10.1128/JB.01980-12 CrossRefPubMedPubMedCentral

Ooijevaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, Mulder CJJ, Kuijper EJ (2018) Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect 24:452–462. https://doi.org/10.1016/j.cmi.2017.12.022 CrossRefPubMed

Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, Longshaw C, Wilcox MH (2018) Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile Ribotypes Study Group. Clin Microbiol Infect 24:724–731. https://doi.org/10.1016/j.cmi.2017.10.008 CrossRefPubMed

10.

Baghani A, Ghourchian S, Aliramezani A, Yaseri M, Mesdaghinia A, Douraghi M (2018) Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients. J Appl Microbiol 125:1518–1525. https://doi.org/10.1111/jam.14035 CrossRefPubMed

11.

Vuotto C, Donelli G, Buckley A, Chilton C (2018) Clostridium difficile biofilm. Adv Exp Med Biol 1050:97–115. https://doi.org/10.1007/978-3-319-72799-8_7 CrossRefPubMed

12.

Cicero AF, Baggioni A (2016) Berberine and its role in chronic disease. Adv Exp Med Biol 928:27–45. https://doi.org/10.1007/978-3-319-41334-1 CrossRefPubMed

13.

Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD (2018) Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol 9:557. https://doi.org/10.3389/fphar.2018.00557 CrossRefPubMedPubMedCentral

14.

Silvester AJ, Aseer KR, Yun JW (2018) Dietary polyphenols and their roles in fat browning. J Nutr Biochem 64:1–12. https://doi.org/10.1016/j.jnutbio.2018.09.028 CrossRefPubMed

15.

Rabbani GHBT, Knight J, Sanyal SC, Alam K (1987) Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholera. J Infect Dis 155:979–984. https://doi.org/10.1093/infdis/155.5.979 CrossRefPubMed

16.

Lv Z, Peng G, Liu W, Xu H, Su J (2015) Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. Antimicrob Agents Chemother 59:3726–3735. https://doi.org/10.1128/AAC.04794-14 CrossRefPubMedPubMedCentral

17.

Wang S, Setlow B, Setlow P, Li YQ (2016) Uptake and levels of the antibiotic berberine in individual dormant and germinating Clostridium difficile and Bacillus cereus spores as measured by laser tweezers Raman spectroscopy. J Antimicrob Chemother 71:1540–1546. https://doi.org/10.1093/jac/dkv504 CrossRefPubMed

18.

Jiang H, Zhang D, He J, Han X, Lin J, Lan Y, Xiong X, Yu L, Yang M, Han L (2018) A novel method to mask the bitter taste of berberine hydrochloride: powder surface modification. Pharmacogn Mag 14:253–260. https://doi.org/10.4103/pm.pm_114_17 CrossRefPubMedPubMedCentral

19.

Shi C, Li M, Muhammad I, Ma X, Chang Y, Li R, Li C, He J, Liu F (2018) Combination of berberine and ciprofloxacin reduces multi-resistant Salmonella strain biofilm formation by depressing mRNA expressions of luxS, rpoE, and ompR. J Vet Sci 19:808–816. https://doi.org/10.4142/jvs.2018.19.6.808 CrossRefPubMedPubMedCentral

20.

Piotrowski M, Karpiński P, Pituch H, van Belkum A, Obuch-Woszczatyński P (2017) Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile. Eur J Clin Microbiol Infect Dis 36:1661–1664. https://doi.org/10.1007/s10096-017-2980 CrossRefPubMed

21.

Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40:175–179CrossRef

22.

Piotrowski M, Wultańska D, Obuch-Woszczatyński P, Pituch H (2019) Fructooligosaccharides and mannose affect Clostridium difficile adhesion and biofilm formation in a concentration-dependent manner. Eur J Clin Microbiol Infect Dis 38:1975–1984. https://doi.org/10.1007/s10096-019-03635-7 CrossRefPubMedPubMedCentral

23.

Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102. https://doi.org/10.1186/gb-2009-10-9-r102 CrossRefPubMedPubMedCentral

24.

Spigaglia P (2016) Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 3:23–42. https://doi.org/10.1177/2049936115622891 CrossRefPubMedPubMedCentral

25.

Roshan N, Riley TV, Knight DR, Steer JH, Hammer KA (2019) Natural products show diverse mechanisms of action against Clostridium difficile. J Appl Microbiol 126:468–479. https://doi.org/10.1111/jam.14152 CrossRefPubMed

26.

Tong L, Xie C, Wei Y, Qu Y, Liang H, Zhang Y, Xu T, Qian X, Qiu H, Deng H (2019) Antitumor effects of berberine on gliomas via inactivation of caspase-1-mediated IL-1β and IL-18 release. Front Oncol 9:364. https://doi.org/10.3389/fonc.2019.00364 CrossRefPubMedPubMedCentral

27.

Wang Y, Yan A, Li S, Liu B, Li H, Yan Y (2019) Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: protocol for a systematic review. Medicine (Baltimore) 98:e16947. https://doi.org/10.1097/MD.0000000000016947 CrossRef

28.

Zhang LS, Zhang JH, Feng R, Jin XY, Yang FW, Ji ZC, Zhao MY, Zhang MY, Zhang BL, Li XM (2019) Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med 47:751–767. https://doi.org/10.1142/S0192415X19500393 CrossRefPubMed

29.

Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, Barrea L, Hassan STS, Šmejkal K, Malaník M, Sychrová A, Barreca D, Ziberna L, Mahomoodally MF, Zengin G, Xu S, Nabavi SM, Shen AZ (2019) Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics 9:1923–1951. https://doi.org/10.7150/thno.30787 CrossRefPubMedPubMedCentral

30.

Chen C, Yu Z, Li Y, Fichna J, Storr M (2014) Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. Am J Chin Med 42:1053–1070. https://doi.org/10.1142/S0192415X14500669 CrossRefPubMed

31.

Tan J, Wang J, Yang C, Zhu C, Guo G, Tang J, Shen H (2019) Antimicrobial characteristics of berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC Complement Altern Med 19:218. https://doi.org/10.1186/s12906-019-2558-9 CrossRefPubMedPubMedCentral

32.

Zuo GY, Li Y, Han J, Wang GC, Zhang YL, Bian ZQ (2012) Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules 17:10322–10330. https://doi.org/10.3390/molecules170910322 CrossRefPubMedPubMedCentral

33.

Wojtyczka RD, Dziedzic A, Kępa M, Kubina R, Kabała-Dzik A, Mularz T, Idzik D (2014) Berberine enhances the antibacterial activity of selected antibiotics against coagulase-negative Staphylococcus strains in vitro. Molecules 19:6583–6596. https://doi.org/10.3390/molecules19056583 CrossRefPubMedPubMedCentral

34.

Liang RM, Yong XL, Duan YQ, Tan YH, Zeng P, Zhou ZY, Jiang Y, Wang SH, Jiang YP, Huang XC, Dong ZH, Hu TT, Shi HQ, Li N (2014) Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). World J Microbiol Biotechnol 30:2861–2869. https://doi.org/10.1007/s11274-014-1712-2 CrossRefPubMed

35.

Baban ST, Kuehne SA, Barketi-Klai A, Cartman ST, Kelly ML, Hardie KR, Kansau I, Collignon A, Minton NP (2013) The role of flagella in Clostridium difficile pathogenesis: comparison between a non-epidemic and an epidemic strain. PLoS One 8:e73026. https://doi.org/10.1371/journal.pone.0073026 CrossRefPubMedPubMedCentral

Title: The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile
Authors: Dorota Wultańska
Michał Piotrowski
Hanna Pituch
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Vancomycin
Clostridioides Difficile
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-03857-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2020

Clinical impact of rapid susceptibility testing on Mueller-Hinton Rapid-SIR directly from urine specimens

Influenza and antiviral resistance: an overview

Prevalence of respiratory viruses and antiviral MxA responses in children with febrile urinary tract infection

Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome

Classification of COVID-19 patients from chest CT images using multi-objective differential evolution–based convolutional neural networks

Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page